Efficacy and Safety of Dual GLP ‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis
Authors' conclusion
Dual GLP-1/GCGR agonists produce meaningful weight loss and metabolic improvements with acceptable short-term safety
Study context
- Population
- Adults with overweight/obesity in RCTs19 RCTs
- Comparison
- Dual GLP-1/GCGR agonists vs controls
- Outcome
- Body weight
Methodological detailsrandom-effects meta-analysis, GRADE, subgroup, sensitivity and publication bias analyses
- Random-effects meta-analysis
- GRADE
- Subgroup, sensitivity and publication bias analyses
Pooled result
As reported in the abstract
MD
−6.65 kg
absolute body weight; moderate certainty
MD
−7.15 %
relative weight
Relative risk
4.75
≥ 5% weight loss; low certainty
Further pooled results
Metabolic outcomes
- Significant improvements in HbA1c, BMI, waist circumference, systolic blood pressure and triglycerides
Safety
| Outcome | RR |
|---|---|
| Any adverse eventsDual agonists vs Controls · more frequent with dual agonists | 1.16 |
| Serious adverse eventsDual agonists vs Controls · did not differ; high certainty | 0.90 |
Original publication
Efficacy and Safety of Dual GLP ‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis. Diabetes Obes Metab. Published 29 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →